APA (7th ed.) Citation

AM, M., Z, N., KR, R., JM, K., JM, W., K, F., . . . CR, F. (2023). Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration. The oncologist, 28(9), 804. https://doi.org/10.1093/oncolo/oyad172

Chicago Style (17th ed.) Citation

AM, Moore, et al. "Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration." The Oncologist 28, no. 9 (2023): 804. https://doi.org/10.1093/oncolo/oyad172.

MLA (9th ed.) Citation

AM, Moore, et al. "Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration." The Oncologist, vol. 28, no. 9, 2023, p. 804, https://doi.org/10.1093/oncolo/oyad172.